Skip to main content
. 2020 Jun 3;11:917. doi: 10.3389/fimmu.2020.00917

Figure 3.

Figure 3

Quantitative myasthenia gravis (QMG) score change from baseline over 12 weeks for eculizumab vs. placebo. Using patient data at the end of both period visits, overall change in mean QMG total score was significantly different between eculizumab and placebo (−7.92 vs. −3.67; paired t-test p = 0.0144). Using patient data at all visits, overall change in mean QMG total score was significantly different between eculizumab and placebo (−6.43 vs. −3.18; repeated-measures mixed model p < 0.0001). Modified from Howard et al. (48).